Cargando…
Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a life-threatening complication associated with high medical costs. Factor Xa inhibitors gradually replace approved treatment with intravenous direct thrombin inhibitors despite their off-label indication, because of easier management and favorable economic...
Autores principales: | Tuleja, Aleksandra, Salvador, Dante, Muka, Taulant, Bernhard, Sarah, Lenz, Armando, Baumgartner, Iris, Schindewolf, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131923/ https://www.ncbi.nlm.nih.gov/pubmed/35147675 http://dx.doi.org/10.1182/bloodadvances.2022007017 |
Ejemplares similares
-
Inhibition of NADPH oxidase blocks NETosis and reduces thrombosis in heparin-induced thrombocytopenia
por: Leung, Halina H. L., et al.
Publicado: (2021) -
ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
por: Karnes, Jason H., et al.
Publicado: (2022) -
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021) -
CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy
por: Cordero-Sanchez, Celia, et al.
Publicado: (2022) -
The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis
por: Hsu, Charles, et al.
Publicado: (2022)